EA007731B1 - N-(2-бромфенил)-n'-[((r)-1-(5-трифторметил-2-пиридил)пирролидин-3-ил)]мочевина, ее соли или сольваты, способ ее получения, фармацевтическая композиция на ее основе, применение и способ лечения и/или профилактики - Google Patents

N-(2-бромфенил)-n'-[((r)-1-(5-трифторметил-2-пиридил)пирролидин-3-ил)]мочевина, ее соли или сольваты, способ ее получения, фармацевтическая композиция на ее основе, применение и способ лечения и/или профилактики Download PDF

Info

Publication number: EA007731B1
Authority: EA; Eurasian Patent Office
Prior art keywords: pain; disorders; pharmaceutically acceptable; neuropathy; formula
Prior art date: 2001-09-13

Application number

EA200400432A

Other languages

English (en)

Russian (ru)

Other versions

EA200400432A1 (ru

Inventor

Харшад Кантилал Рами

Мервин Томпсон

Пол Эдриан Вайман

Original Assignee

Смитклайн Бичам Плс

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-13

Filing date

2002-09-13

Publication date

2006-12-29

2001-09-13 Priority claimed from GB0122156A external-priority patent/GB0122156D0/en

2001-12-20 Priority claimed from GB0130505A external-priority patent/GB0130505D0/en

2001-12-20 Priority claimed from GB0130547A external-priority patent/GB0130547D0/en

2001-12-20 Priority claimed from GB0130503A external-priority patent/GB0130503D0/en

2002-09-13 Application filed by Смитклайн Бичам Плс filed Critical Смитклайн Бичам Плс

2004-12-30 Publication of EA200400432A1 publication Critical patent/EA200400432A1/ru

2006-12-29 Publication of EA007731B1 publication Critical patent/EA007731B1/ru

Links

150000003839 salts Chemical class 0.000 title claims abstract description 29
239000012453 solvate Substances 0.000 title claims abstract description 21
238000000034 method Methods 0.000 title claims abstract description 15
238000002360 preparation method Methods 0.000 title claims abstract description 8
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
238000011282 treatment Methods 0.000 title claims description 12
238000011321 prophylaxis Methods 0.000 title description 2
JYILLRHXRVTRSH-GFCCVEGCSA-N 1-(2-bromophenyl)-3-[(3r)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]urea Chemical compound N1=CC(C(F)(F)F)=CC=C1N1C[C@H](NC(=O)NC=2C(=CC=CC=2)Br)CC1 JYILLRHXRVTRSH-GFCCVEGCSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 48
239000003814 drug Substances 0.000 claims abstract description 17
208000002193 Pain Diseases 0.000 claims description 31
230000036407 pain Effects 0.000 claims description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
208000035475 disorder Diseases 0.000 claims description 15
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
-1 (5-trifluoromethyl-2-pyridyl) pyrrolidin-3yl Chemical group 0.000 claims description 8
201000001119 neuropathy Diseases 0.000 claims description 8
230000007823 neuropathy Effects 0.000 claims description 8
208000033808 peripheral neuropathy Diseases 0.000 claims description 8
102000011040 TRPV Cation Channels Human genes 0.000 claims description 7
108010062740 TRPV Cation Channels Proteins 0.000 claims description 7
125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims description 6
206010020751 Hypersensitivity Diseases 0.000 claims description 6
208000003251 Pruritus Diseases 0.000 claims description 6
208000026935 allergic disease Diseases 0.000 claims description 6
239000004202 carbamide Substances 0.000 claims description 6
201000006549 dyspepsia Diseases 0.000 claims description 6
230000009610 hypersensitivity Effects 0.000 claims description 6
208000004296 neuralgia Diseases 0.000 claims description 6
210000004197 pelvis Anatomy 0.000 claims description 6
208000006673 asthma Diseases 0.000 claims description 5
208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 5
201000006417 multiple sclerosis Diseases 0.000 claims description 5
208000023504 respiratory system disease Diseases 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 4
230000009286 beneficial effect Effects 0.000 claims description 4
230000007803 itching Effects 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
GOOVAYJIVMBWPP-UHFFFAOYSA-N 1-bromo-2-isocyanatobenzene Chemical compound BrC1=CC=CC=C1N=C=O GOOVAYJIVMBWPP-UHFFFAOYSA-N 0.000 claims description 3
RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 claims description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
208000000094 Chronic Pain Diseases 0.000 claims description 3
206010011224 Cough Diseases 0.000 claims description 3
208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
208000001640 Fibromyalgia Diseases 0.000 claims description 3
206010018691 Granuloma Diseases 0.000 claims description 3
206010019233 Headaches Diseases 0.000 claims description 3
206010061218 Inflammation Diseases 0.000 claims description 3
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
206010054949 Metaplasia Diseases 0.000 claims description 3
208000019695 Migraine disease Diseases 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 claims description 3
208000028389 Nerve injury Diseases 0.000 claims description 3
206010029240 Neuritis Diseases 0.000 claims description 3
206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
208000004550 Postoperative Pain Diseases 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
206010038419 Renal colic Diseases 0.000 claims description 3
208000008765 Sciatica Diseases 0.000 claims description 3
206010046543 Urinary incontinence Diseases 0.000 claims description 3
206010047700 Vomiting Diseases 0.000 claims description 3
230000008485 antagonism Effects 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
206010009887 colitis Diseases 0.000 claims description 3
201000003146 cystitis Diseases 0.000 claims description 3
210000003238 esophagus Anatomy 0.000 claims description 3
231100000869 headache Toxicity 0.000 claims description 3
208000024798 heartburn Diseases 0.000 claims description 3
208000027866 inflammatory disease Diseases 0.000 claims description 3
230000004054 inflammatory process Effects 0.000 claims description 3
208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
208000028867 ischemia Diseases 0.000 claims description 3
230000015689 metaplastic ossification Effects 0.000 claims description 3
206010027599 migraine Diseases 0.000 claims description 3
230000008764 nerve damage Effects 0.000 claims description 3
208000021722 neuropathic pain Diseases 0.000 claims description 3
201000008482 osteoarthritis Diseases 0.000 claims description 3
229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
230000009747 swallowing Effects 0.000 claims description 3
208000004371 toothache Diseases 0.000 claims description 3
208000009935 visceral pain Diseases 0.000 claims description 3
230000008673 vomiting Effects 0.000 claims description 3
208000007107 Stomach Ulcer Diseases 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims description 2
208000003295 carpal tunnel syndrome Diseases 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
208000000718 duodenal ulcer Diseases 0.000 claims description 2
210000002784 stomach Anatomy 0.000 claims description 2
206010006482 Bronchospasm Diseases 0.000 claims 2
208000008930 Low Back Pain Diseases 0.000 claims 2
230000007885 bronchoconstriction Effects 0.000 claims 2
210000000936 intestine Anatomy 0.000 claims 1
230000005906 menstruation Effects 0.000 claims 1
210000005036 nerve Anatomy 0.000 claims 1
230000004770 neurodegeneration Effects 0.000 claims 1
CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 claims 1
208000011580 syndromic disease Diseases 0.000 claims 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
239000000243 solution Substances 0.000 description 13
229940079593 drug Drugs 0.000 description 11
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 10
239000000203 mixture Substances 0.000 description 9
239000002253 acid Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
235000017663 capsaicin Nutrition 0.000 description 5
229960002504 capsaicin Drugs 0.000 description 5
239000000085 vanilloid receptor antagonist Substances 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
239000011575 calcium Substances 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000000872 buffer Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
150000003672 ureas Chemical class 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
241000700198 Cavia Species 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
208000004454 Hyperalgesia Diseases 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000003708 ampul Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
GJKCYSMZYSMYRW-UHFFFAOYSA-N 1-(4-methoxyphenyl)-3-(1-phenylpyrrolidin-3-yl)urea Chemical compound C1=CC(OC)=CC=C1NC(=O)NC1CN(C=2C=CC=CC=2)CC1 GJKCYSMZYSMYRW-UHFFFAOYSA-N 0.000 description 1
DWYHJOLGUSRZSO-UHFFFAOYSA-N 1-phenyl-3-(1-phenylpyrrolidin-3-yl)urea Chemical compound C=1C=CC=CC=1NC(=O)NC(C1)CCN1C1=CC=CC=C1 DWYHJOLGUSRZSO-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
206010006487 Bronchostenosis Diseases 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000035154 Hyperesthesia Diseases 0.000 description 1
239000007987 MES buffer Substances 0.000 description 1
OPZKBPQVWDSATI-KHPPLWFESA-N N-Vanillyloleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-KHPPLWFESA-N 0.000 description 1
206010029216 Nervousness Diseases 0.000 description 1
240000000275 Persicaria hydropiper Species 0.000 description 1
235000017337 Persicaria hydropiper Nutrition 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
DRCMAZOSEIMCHM-UHFFFAOYSA-N capsazepine Chemical compound C1C=2C=C(O)C(O)=CC=2CCCN1C(=S)NCCC1=CC=C(Cl)C=C1 DRCMAZOSEIMCHM-UHFFFAOYSA-N 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
238000002690 local anesthesia Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 1
OPZKBPQVWDSATI-UHFFFAOYSA-N oleoyl vanillylamide Natural products CCCCCCCCC=CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-UHFFFAOYSA-N 0.000 description 1
229950010717 olvanil Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
229960003081 probenecid Drugs 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
230000001003 psychopharmacologic effect Effects 0.000 description 1
XGBULVIMVCHZSV-UHFFFAOYSA-N pyrrolidin-3-ylurea Chemical class NC(=O)NC1CCNC1 XGBULVIMVCHZSV-UHFFFAOYSA-N 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
150000003555 thioacetals Chemical class 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Hydrogenated Pyridines (AREA)

EA200400432A 2001-09-13 2002-09-13 N-(2-бромфенил)-n'-[((r)-1-(5-трифторметил-2-пиридил)пирролидин-3-ил)]мочевина, ее соли или сольваты, способ ее получения, фармацевтическая композиция на ее основе, применение и способ лечения и/или профилактики EA007731B1 (ru)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GB0122156A GB0122156D0 (en)	2001-09-13	2001-09-13	Novel compounds
GB0130505A GB0130505D0 (en)	2001-12-20	2001-12-20	Novel compounds
GB0130547A GB0130547D0 (en)	2001-12-20	2001-12-20	Novel compounds
GB0130503A GB0130503D0 (en)	2001-12-20	2001-12-20	Novel compounds
PCT/GB2002/004206 WO2003022809A2 (fr)	2001-09-13	2002-09-13	Nouveaux composes

Publications (2)

Publication Number	Publication Date
EA200400432A1 EA200400432A1 (ru)	2004-12-30
EA007731B1 true EA007731B1 (ru)	2006-12-29

Family

ID=27447989

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EA200400432A EA007731B1 (ru)	2001-09-13	2002-09-13	N-(2-бромфенил)-n'-[((r)-1-(5-трифторметил-2-пиридил)пирролидин-3-ил)]мочевина, ее соли или сольваты, способ ее получения, фармацевтическая композиция на ее основе, применение и способ лечения и/или профилактики

Country Status (31)

Country	Link
US (1)	US8063078B2 (fr)
EP (3)	EP2298757A3 (fr)
JP (2)	JP4463552B2 (fr)
KR (3)	KR20100082390A (fr)
CN (1)	CN1247568C (fr)
AP (1)	AP1818A (fr)
AR (1)	AR038786A1 (fr)
AT (1)	ATE420083T1 (fr)
AU (1)	AU2002329397B2 (fr)
BR (1)	BR0212468A (fr)
CA (1)	CA2458632C (fr)
CY (1)	CY1109449T1 (fr)
DE (1)	DE60230773D1 (fr)
DK (1)	DK1425277T3 (fr)
EA (1)	EA007731B1 (fr)
ES (1)	ES2316607T3 (fr)
HU (1)	HUP0401923A3 (fr)
IL (2)	IL160755A0 (fr)
MA (1)	MA26216A1 (fr)
MX (1)	MXPA04002379A (fr)
MY (1)	MY138086A (fr)
NO (3)	NO327009B1 (fr)
NZ (1)	NZ531137A (fr)
OA (1)	OA12659A (fr)
PE (1)	PE20030417A1 (fr)
PL (1)	PL213639B1 (fr)
PT (1)	PT1425277E (fr)
SI (1)	SI1425277T1 (fr)
TW (1)	TWI283665B (fr)
UY (1)	UY27446A1 (fr)
WO (1)	WO2003022809A2 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY138086A (en) *	2001-09-13	2009-04-30	Smithkline Beecham Plc	Novel urea derivative as vanilloid receptor-1 antagonist
DK1472225T3 (da)	2002-02-01	2010-08-09	Euro Celtique Sa	2-Piperazinpyridiner, som er anvendelige til behandling af smerte
CA2476936A1 (fr) *	2002-02-20	2003-08-28	Chih-Hung Lee	Composes azabicycliques fusionnes qui inhibent le recepteur (vr1) sous-type 1 du recepteur vanilloide
US7074805B2 (en)	2002-02-20	2006-07-11	Abbott Laboratories	Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US6974818B2 (en)	2002-03-01	2005-12-13	Euro-Celtique S.A.	1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
ES2300613T3 (es)	2002-06-28	2008-06-16	Euro-Celtique S.A.	Derivados terapeuticos de piperacina utiles para tratar el dolor.
US7262194B2 (en)	2002-07-26	2007-08-28	Euro-Celtique S.A.	Therapeutic agents useful for treating pain
GB0221157D0 (en) *	2002-09-12	2002-10-23	Glaxo Group Ltd	Novel treatment
AU2003270199A1 (en) *	2002-09-13	2004-04-30	Glaxo Group Limited	Urea compounds active as vanilloid receptor antagonists for the treatment of pain
US7157462B2 (en)	2002-09-24	2007-01-02	Euro-Celtique S.A.	Therapeutic agents useful for treating pain
WO2004052846A1 (fr)	2002-12-06	2004-06-24	Bayer Healthcare Ag	Derives de tetrahydro-naphthalene
GB0229808D0 (en) *	2002-12-20	2003-01-29	Glaxo Group Ltd	Novel compositions
US6933311B2 (en) *	2003-02-11	2005-08-23	Abbott Laboratories	Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
ES2330107T3 (es)	2003-03-06	2009-12-04	Glaxo Group Limited	Derivados de urea heterociclicos para el tratamiento del dolor.
WO2004078744A2 (fr) *	2003-03-07	2004-09-16	Glaxo Group Limited	Derives d'uree
GB0305426D0 (en) *	2003-03-08	2003-04-16	Glaxo Group Ltd	Novel compounds
SE0301446D0 (sv)	2003-05-16	2003-05-16	Astrazeneca Ab	New Compounds
ATE556067T1 (de)	2003-05-20	2012-05-15	Ajinomoto Kk	Modulatoren des vanilloid rezeptors
EP1493438A1 (fr) *	2003-07-03	2005-01-05	Bayer HealthCare AG	Inhibiteurs du recepteur vanilloide (VR1) dans le traitement de la douleur associée au VIH
GB0319150D0 (en)	2003-08-14	2003-09-17	Glaxo Group Ltd	Novel compounds
GB0319151D0 (en) *	2003-08-14	2003-09-17	Glaxo Group Ltd	Novel compounds
WO2005040119A1 (fr) *	2003-10-01	2005-05-06	Bayer Healthcare Ag	Tetrahydro-naphtalene et derives d'uree
EP1679296A4 (fr)	2003-10-14	2007-12-26	Ajinomoto Kk	Derive ethere
JP2007509846A (ja) *	2003-10-15	2007-04-19	バイエル・ヘルスケア・アクチェンゲゼルシャフト	テトラヒドロ−ナフタレンおよび尿素誘導体
EP1685112B1 (fr)	2003-11-08	2011-07-20	Bayer Schering Pharma Aktiengesellschaft	Derives de tetrahydro-quinolinyluree
WO2005095327A1 (fr)	2004-03-31	2005-10-13	Ajinomoto Co., Inc.	Dérivés d'aniline
WO2006002361A2 (fr)	2004-06-24	2006-01-05	Incyte Corporation	2-methylpropanamides et leur utilisation comme produits pharmaceutiques
JP2008508190A (ja)	2004-07-19	2008-03-21	ノボノルディスクアクティーゼルスカブ	肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害
KR20060087386A (ko)	2005-01-28	2006-08-02	주식회사 대웅제약	신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006098554A1 (fr) *	2005-03-16	2006-09-21	Amorepacific Corporation	Nouveaux composes, isomere de ceux-ci ou sels pharmaceutiquement acceptables de ceux-ci en tant qu’antagonistes du recepteur vanilloide ; et composition pharmaceutique contenant ceux-ci
WO2007046867A2 (fr) *	2005-05-19	2007-04-26	Xenon Pharmaceuticals Inc.	Derives de piperidine et leurs utilisations comme agents therapeutiques
UY30048A1 (es)	2005-12-23	2007-07-31	Astrazeneca Ab	Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
EP1889830A1 (fr) *	2006-07-10	2008-02-20	Pharmeste S.r.l.	Amides biarylcarboxyaryles en tant que modulateurs du recepteur vanilloid-1.
EP1882687A1 (fr) *	2006-07-27	2008-01-30	Amorepacific Corporation	Composés hétérocycliques, leur utilisation comme antagonistes du récepteur vanilloide et les compositions pharmaceutiques qui les contiennent
PL2054411T3 (pl) *	2006-07-27	2015-02-27	Amorepacific Corp	Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
TWI433839B (zh)	2006-08-11	2014-04-11	Neomed Inst	新穎的苯并咪唑衍生物290
TW200824687A (en)	2006-08-25	2008-06-16	Abbott Lab	Compounds that inhibit TRPV1 and uses thereof
US8030504B2 (en)	2006-12-20	2011-10-04	Abbott Laboratories	Antagonists of the TRPV1 receptor and uses thereof
MX2010010262A (es)	2008-03-20	2010-12-06	Abbott Lab	Metodos para la elaboracion de agentes para el sistema nervioso central que son antagonistas del trpv1.
EP2264031B1 (fr)	2008-04-18	2015-04-15	Daewoong Pharmaceutical Co., Ltd.	Nouveau dérivé de benzoxazine benzimidazole, composition pharmaceutique le comprenant et application s'y rapportant
US8367835B2 (en)	2008-05-07	2013-02-05	Dainippon Sumitomo Pharma Co., Ltd.	Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same
WO2010026128A1 (fr) *	2008-09-02	2010-03-11	Glaxo Group Limited	N-(3-méthyl-5-isoquinolinyl)-n'-((3r)-l-[5-(trifluorométhyl)-2-pyridinyl]-3-pyrrolidinyl) urée pour le traitement de la rhinite
JP2012501315A (ja) *	2008-09-02	2012-01-19	グラクソグループリミテッド	鼻炎を治療するためのｔｒｐｖｌアンタゴニストｓｂ−７０５４９８
JP2013028536A (ja) *	2009-11-11	2013-02-07	Dainippon Sumitomo Pharma Co Ltd	環状アミン−１−カルボン酸エステル誘導体およびそれを含有する医薬組成物
WO2012045729A1 (fr)	2010-10-05	2012-04-12	Glaxo Group Limited	Dérivés d'imidazo[1,2-a]pyridine et de pyrazolo[1,5-a]pyridine en tant qu'antagonistes du trpv1
KR101293384B1 (ko)	2010-10-13	2013-08-05	주식회사 대웅제약	신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
WO2012072512A1 (fr)	2010-11-29	2012-06-07	Glaxo Group Limited	Carboxamides de n-cyclo-butylimidazopyridine ou de n-cyclo-pyrazolopyridine comme antagonistes de trpv1
GB201101517D0 (en) *	2011-01-28	2011-03-16	Proximagen Ltd	Receptor antagonists
EP2697221A1 (fr)	2011-04-11	2014-02-19	Glaxo Group Limited	N-cyclobutyl-imidazopyridine-méthylamine à titre d'antagoniste des trpv1
DE102022104759A1 (de)	2022-02-28	2023-08-31	SCi Kontor GmbH	Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Citations (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3424761A (en) *	1966-03-07	1969-01-28	Robins Co Inc A H	3-ureidopyrrolidines
US3424760A (en) *	1966-03-07	1969-01-28	Robins Co Inc A H	3-ureidopyrrolidines
US4001422A (en) *	1974-07-25	1977-01-04	Pfizer Inc.	4-aminoquinazoline cardiac stimulants
WO1992019618A1 (fr) *	1991-05-03	1992-11-12	Abbott Laboratories	Antagonistes d'activation plaquettaires
EP0790240A1 (fr) *	1996-02-15	1997-08-20	Tanabe Seiyaku Co., Ltd.	Dérivés de phénol ayant une activité pharmaceutique et procédés pour leur préparation
WO1999000128A1 (fr) *	1997-06-26	1999-01-07	Eli Lilly And Company	Agents antithrombotiques
WO1999000121A1 (fr) *	1997-06-26	1999-01-07	Eli Lilly And Company	Agents antithrombotiques
WO2001028987A1 (fr) *	1999-10-15	2001-04-26	Du Pont Pharmaceuticals Company	Amines benzyle cycloalkyle comme modulateurs de l'activite du recepteur de la chimiokine
JP2002088073A (ja) *	2000-09-08	2002-03-27	Yamanouchi Pharmaceut Co Ltd	抗アンドロゲン剤
WO2002090326A1 (fr) *	2001-05-02	2002-11-14	Smithkline Beecham P.L.C.	Urees heterocycliques, leur preparation et leur utilisation comme antagonistes du recepteur vanilloide

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE68918991T2 (de)	1988-06-17	1995-04-27	Procter & Gamble	Anwendung von Vanillin-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Herpes simplex-Infektion.
HU206082B (en)	1988-12-23	1992-08-28	Sandoz Ag	Process for producing capsaicin derivatives and pharmaceutical compositions comprising such compounds
CA2017383A1 (fr)	1989-06-08	1990-12-08	Raymond R. Martodam	Utilisation de vanilloides pour le traitement des affections ou des troubles respiratoires
WO1992009285A1 (fr)	1990-11-27	1992-06-11	The Procter & Gamble Company	Combinaisons de composes vanilloides et de composes phosphonates antiviraux pour le traitement d'infections par herpes
JP2000080085A (ja)	1997-09-01	2000-03-21	Kyorin Pharmaceut Co Ltd	６，７−非対称ジ置換キノキサリンカルボン酸誘導体とその付加塩及びそれらの製造方法
WO2000050387A1 (fr)	1999-02-22	2000-08-31	Pacific Corporation	Analogues de vanilloide contenant des pharmacophores de resiniferatoxine, utilises en tant qu'agonistes du recepteur de vanilloide et analgesiques puissants, compositions et leurs utilisations
HUP0202248A3 (en)	1999-03-12	2006-06-28	Boehringer Ingelheim Pharma	Compounds useful as anti-inflammatory agents
WO2002008221A2 (fr)	2000-07-20	2002-01-31	Neurogen Corporation	Ligands du recepteur de la capsicine
WO2002016318A1 (fr)	2000-08-21	2002-02-28	Pacific Corporation	Nouveaux derives de thiourea et compositions pharmaceutiques renfermant ceux-ci
WO2002016317A1 (fr)	2000-08-21	2002-02-28	Pacific Corporation	Nouveaux derives d'acide thiocarbamique et compositions pharmaceutiques contenant lesdits derives
DE60120421T2 (de)	2000-08-21	2006-12-28	Pacific Corp.	Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten
JP2002080073A (ja)	2000-09-07	2002-03-19	Kyokuto Kobunshi Kk	電子レンジ用自動開孔袋
MY138086A (en) *	2001-09-13	2009-04-30	Smithkline Beecham Plc	Novel urea derivative as vanilloid receptor-1 antagonist
AU2003247772A1 (en) *	2002-06-27	2004-01-19	Schering Aktiengesellschaft	Substituted quinoline ccr5 receptor antagonists
AU2003270199A1 (en) *	2002-09-13	2004-04-30	Glaxo Group Limited	Urea compounds active as vanilloid receptor antagonists for the treatment of pain
GB0229808D0 (en)	2002-12-20	2003-01-29	Glaxo Group Ltd	Novel compositions
CA2563494A1 (fr)	2004-04-20	2005-11-03	Bayer Healthcare Ag	Derives d'uree utilises en tant qu'antagonistes du recepteur vanilloide (vr1)

2002
- 2002-09-11 MY MYPI20023391A patent/MY138086A/en unknown
- 2002-09-11 PE PE2002000895A patent/PE20030417A1/es not_active Application Discontinuation
- 2002-09-11 TW TW091120671A patent/TWI283665B/zh not_active IP Right Cessation
- 2002-09-12 UY UY27446A patent/UY27446A1/es not_active Application Discontinuation
- 2002-09-12 AR ARP020103454A patent/AR038786A1/es active IP Right Grant
- 2002-09-13 IL IL16075502A patent/IL160755A0/xx unknown
- 2002-09-13 DE DE60230773T patent/DE60230773D1/de not_active Expired - Lifetime
- 2002-09-13 AU AU2002329397A patent/AU2002329397B2/en not_active Ceased
- 2002-09-13 PL PL369026A patent/PL213639B1/pl not_active IP Right Cessation
- 2002-09-13 JP JP2003526885A patent/JP4463552B2/ja not_active Expired - Fee Related
- 2002-09-13 EP EP10179466A patent/EP2298757A3/fr not_active Withdrawn
- 2002-09-13 OA OA1200400070A patent/OA12659A/en unknown
- 2002-09-13 KR KR1020107014626A patent/KR20100082390A/ko not_active Ceased
- 2002-09-13 HU HU0401923A patent/HUP0401923A3/hu unknown
- 2002-09-13 AT AT02765023T patent/ATE420083T1/de active
- 2002-09-13 EP EP08172882A patent/EP2036902A3/fr not_active Withdrawn
- 2002-09-13 MX MXPA04002379A patent/MXPA04002379A/es active IP Right Grant
- 2002-09-13 CA CA2458632A patent/CA2458632C/fr not_active Expired - Fee Related
- 2002-09-13 KR KR1020097003812A patent/KR100955967B1/ko not_active Expired - Fee Related
- 2002-09-13 BR BR0212468-8A patent/BR0212468A/pt not_active IP Right Cessation
- 2002-09-13 CN CNB028177177A patent/CN1247568C/zh not_active Expired - Fee Related
- 2002-09-13 DK DK02765023T patent/DK1425277T3/da active
- 2002-09-13 EP EP02765023A patent/EP1425277B8/fr not_active Expired - Lifetime
- 2002-09-13 NZ NZ531137A patent/NZ531137A/en not_active IP Right Cessation
- 2002-09-13 SI SI200230792T patent/SI1425277T1/sl unknown
- 2002-09-13 US US10/489,277 patent/US8063078B2/en not_active Expired - Fee Related
- 2002-09-13 PT PT02765023T patent/PT1425277E/pt unknown
- 2002-09-13 KR KR1020047003680A patent/KR101063679B1/ko not_active Expired - Fee Related
- 2002-09-13 AP APAP/P/2004/002982A patent/AP1818A/en active
- 2002-09-13 ES ES02765023T patent/ES2316607T3/es not_active Expired - Lifetime
- 2002-09-13 EA EA200400432A patent/EA007731B1/ru not_active IP Right Cessation
- 2002-09-13 WO PCT/GB2002/004206 patent/WO2003022809A2/fr not_active Ceased
2004
- 2004-03-04 IL IL160755A patent/IL160755A/en not_active IP Right Cessation
- 2004-03-10 NO NO20041003A patent/NO327009B1/no not_active IP Right Cessation
- 2004-03-12 MA MA27573A patent/MA26216A1/fr unknown
2008
- 2008-12-04 NO NO20085077A patent/NO20085077L/no not_active Application Discontinuation
- 2008-12-04 NO NO20085078A patent/NO20085078L/no unknown
2009
- 2009-03-19 CY CY20091100306T patent/CY1109449T1/el unknown
- 2009-12-08 JP JP2009278584A patent/JP2010100632A/ja active Pending

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3424761A (en) *	1966-03-07	1969-01-28	Robins Co Inc A H	3-ureidopyrrolidines
US3424760A (en) *	1966-03-07	1969-01-28	Robins Co Inc A H	3-ureidopyrrolidines
US4001422A (en) *	1974-07-25	1977-01-04	Pfizer Inc.	4-aminoquinazoline cardiac stimulants
WO1992019618A1 (fr) *	1991-05-03	1992-11-12	Abbott Laboratories	Antagonistes d'activation plaquettaires
EP0790240A1 (fr) *	1996-02-15	1997-08-20	Tanabe Seiyaku Co., Ltd.	Dérivés de phénol ayant une activité pharmaceutique et procédés pour leur préparation
WO1999000128A1 (fr) *	1997-06-26	1999-01-07	Eli Lilly And Company	Agents antithrombotiques
WO1999000121A1 (fr) *	1997-06-26	1999-01-07	Eli Lilly And Company	Agents antithrombotiques
WO2001028987A1 (fr) *	1999-10-15	2001-04-26	Du Pont Pharmaceuticals Company	Amines benzyle cycloalkyle comme modulateurs de l'activite du recepteur de la chimiokine
JP2002088073A (ja) *	2000-09-08	2002-03-27	Yamanouchi Pharmaceut Co Ltd	抗アンドロゲン剤
WO2002090326A1 (fr) *	2001-05-02	2002-11-14	Smithkline Beecham P.L.C.	Urees heterocycliques, leur preparation et leur utilisation comme antagonistes du recepteur vanilloide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TANIGUCHI, NOBUAKI ET AL.: "Preparation of heterocyclic moiety-containing benzonitrile derivatives as antiandrogen agents", retrieved from STN Database accession no. 136:279475, XP002225002, CAS RN: 405907-66-6; 405907-67-7, abstract & JP 2002088073 A (YAMANOUCHI PHARMACEUTICAL CO., LTD., JAPAN), 27 March 2002 (2002-03-27), examples 6-1,6-2 *
HELSLEY G. C. ET AL.: "SYNTHESIS AND BIOLOGICAL ACTIVITY OF SOME 1-SUBSITUTED 3-PYRROLIDINYLUREAS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 11, no. 5, September 1968 (1968-09), pages 1034-1037, XP001095126, ISSN: 0022-2623, examples 38, 40; table III *
MASTERS JOHN J. ET AL.: "Non-Amidine-Containing 1,2-Dibenzamidobenzene Inhibitors of Human Factor Xa with Potent Anticoagulant and Antithrombotic Activity", JOURNAL OF MEDICINAL CHEMISTRY (2000), 43(11), 2087-2092, XP002238143, abstract, examples 13, 15, 18, 20, 22-25 *
PAN P.-C. ET AL.: "Soluble Polymer-Supported Synthesis of Arylpiperazines", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 39, no. 51, 17 December 1998 (1998-12-17), pages 9505-9508, XP004144238, ISSN: 0040-4039, example 10C *

Also Published As

Publication number	Publication date
NZ531137A (en)	2006-08-31
EP2036902A3 (fr)	2009-05-06
DK1425277T3 (da)	2009-03-16
KR20090026369A (ko)	2009-03-12
AP1818A (en)	2008-01-07
JP2010100632A (ja)	2010-05-06
UY27446A1 (es)	2003-04-30
HUP0401923A2 (hu)	2005-01-28
WO2003022809A3 (fr)	2003-07-17
HK1066534A1 (en)	2005-03-24
PE20030417A1 (es)	2003-08-06
ES2316607T3 (es)	2009-04-16
EP1425277A2 (fr)	2004-06-09
AP2004002982A0 (en)	2004-03-31
AR038786A1 (es)	2005-01-26
CY1109449T1 (el)	2014-08-13
EP1425277B1 (fr)	2009-01-07
NO20041003L (no)	2004-06-04
IL160755A0 (en)	2004-08-31
CN1553905A (zh)	2004-12-08
DE60230773D1 (de)	2009-02-26
WO2003022809A2 (fr)	2003-03-20
MA26216A1 (fr)	2004-07-01
MY138086A (en)	2009-04-30
US8063078B2 (en)	2011-11-22
BR0212468A (pt)	2004-10-19
SI1425277T1 (sl)	2009-04-30
PT1425277E (pt)	2009-03-05
TWI283665B (en)	2007-07-11
NO327009B1 (no)	2009-04-06
CA2458632C (fr)	2011-08-23
EP2036902A2 (fr)	2009-03-18
PL213639B1 (pl)	2013-04-30
US20090163506A1 (en)	2009-06-25
KR20100082390A (ko)	2010-07-16
KR101063679B1 (ko)	2011-09-07
CN1247568C (zh)	2006-03-29
JP2005504074A (ja)	2005-02-10
AU2002329397B2 (en)	2006-04-27
EP1425277B8 (fr)	2009-04-01
PL369026A1 (en)	2005-04-18
JP4463552B2 (ja)	2010-05-19
NO20085077L (no)	2004-06-04
ATE420083T1 (de)	2009-01-15
HUP0401923A3 (en)	2012-09-28
KR100955967B1 (ko)	2010-05-04
IL160755A (en)	2009-09-01
NO20085078L (no)	2004-06-04
EA200400432A1 (ru)	2004-12-30
EP2298757A2 (fr)	2011-03-23
KR20040041610A (ko)	2004-05-17
MXPA04002379A (es)	2004-05-31
EP2298757A3 (fr)	2011-12-28
CA2458632A1 (fr)	2003-03-20
OA12659A (en)	2006-06-19

Legal Events

Date	Code	Title	Description
2015-06-30	MM4A	Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)	Designated state(s): AM AZ BY KZ KG MD TJ TM RU

Publication	Publication Date	Title
EP1425277B1 (fr)	2009-01-07	Derives de l'uree actifs comme antagonistes des recepteurs vanilloides pour le traitement de la douleur
US10227295B2 (en)	2019-03-12	Selective histone deactylase 6 inhibitors
ES2489645T3 (es)	2014-09-02	Compuestos y métodos para inhibir la interacción de proteínas BLC con compañeros de unión
JP5699152B2 (ja)	2015-04-08	リジン特異的デメチラーゼ−１阻害剤およびその使用
EP1664005B1 (fr)	2011-02-09	Utilisation de derives du thiazole comme modulateurs des recepteurs cannabinoides
KR101721025B1 (ko)	2017-03-29	테트라하이드로벤조티오펜 화합물
ES2293993T3 (es)	2008-04-01	Inhibidores de produccion de tnf-alfa.
US20040082661A1 (en)	2004-04-29	Urea derivatives having vanilloid receptor (vr1) antagonist activity
ES2617878T3 (es)	2017-06-20	Inhibidores de tubulina basados en la pirazina
JP2004527571A (ja)	2004-09-09	複素環ウレア、それらの製造およびバニロイド受容体アンタゴニストとしてのそれらの使用
AU2014260605A1 (en)	2015-10-22	Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
EP0712397B1 (fr)	1999-04-21	Derives amides employes comme antagonistes du recepteur 5ht1d
CA3090233A1 (fr)	2019-08-15	Composes destines a l'inhibition de tnik et utilisations medicales associees
AU2008323026B2 (en)	2014-06-19	Drug active in neuropathic pain
DE69411589T2 (de)	1999-01-07	Indol, indolin und chinolin derivate mit einer 5ht1d antagonistischen wirkung
RU2361855C2 (ru)	2009-07-20	Аминобензофеноны
ES2494765T3 (es)	2014-09-16	Compuestos y métodos para inhibir la interacción de proteínas BLC con compañeros de unión
EP1603899B1 (fr)	2009-08-26	Derives d'uree heterocycliques pour le traitement de la douleur
JPWO2005079845A1 (ja)	2007-08-02	片頭痛予防薬
AU2023309042A1 (en)	2024-12-05	Antihistamine compound, and preparation method therefor and use thereof
CA3130529A1 (en)	2018-04-12	Urea derivative
JPWO2005035471A1 (ja)	2006-12-21	エーテル誘導体
CA2393027A1 (fr)	2001-06-21	Inhibiteurs d'expression du gene de l'interleukine 5
US20250214945A1 (en)	2025-07-03	Thiobenzimidazole derivative or pharmaceutically acceptable salt thereof, and use thereof
HK1066534B (en)	2009-10-30	Urea-compounds active as vanilloid receptor antagonists for the treatment of pain